Rewriting protein fate: emerging strategies for targeted protein degradation and associated challenges
Biochemical Society Transactions · 25.11.2026 · 54 (11) · 1607-1621
DOI: 10.1042/bst20250441 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 11.11.2026. Verfasst von Andrea Bertran-Mostazo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cooperative Research in Bioscience (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain. Hauptthemen laut MEDLINE: Proteolysis, Proteins. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades (MCIU), Ministerio de Ciencia e Innovación (MCIN), Diputación Foral de Bizkaia (Bizkaiko Foru Aldundia).
Abstract (Originalsprache)
Classical small-molecule drugs have traditionally relied on an occupancy-driven paradigm that requires tight and sustained binding to a well-defined pocket on the target protein. Targeted protein degradation (TPD) approaches have emerged to overcome the limitations of traditional pharmacology to promote the selective degradation of disease-associated proteins, harnessing the central proteostasis pathways in eukaryotic cells: the ubiquitin proteasome system and the autophagy-lysosomal machinery. Thus, TPD exploits the idea of reprogramming cellular proteostasis for therapeutic benefits, dictating the fate of the target protein by means of degrader molecules that induce proximity between a target protein and components of the degradation machineries. The present review gives an overview of the molecular mechanisms of cellular proteostasis and how they are exploited for drug discovery purposes through TPD strategies. We describe some of the most explored degrader modalities, such as molecular glues, proteolysis targeting chimeras, and lysosomal targeting chimeras, as well as new modalities of degraders, highlighting their major advantages and limitations, and discuss the challenges associated with their development, including ligand identification, target degradability, or the possibility for their rational design. Furthermore, we consider recent advances in the design of these degraders to potentially address those limitations. Together, these insights established TPD as a transformative pharmacological modality that revolutionized drug discovery campaigns since it expands the druggable proteome, offering numerous advantages over traditional drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cooperative Research in Bioscience (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.
ORCID-Profile: Andrea Bertran-Mostazo, Rosa Barrio
Förderung
- Ministerio de Ciencia, Innovación y Universidades (MCIU)
- Ministerio de Ciencia e Innovación (MCIN)
- Diputación Foral de Bizkaia (Bizkaiko Foru Aldundia)
- Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza (Departamento de Desarrollo Económico y Competitividad, Gobierno Vasco)
Zitieren
APA
Bertran-Mostazo, A., & Barrio, R. (2026). Rewriting protein fate: emerging strategies for targeted protein degradation and associated challenges. Biochemical Society Transactions, 54(11), 1607-1621. https://doi.org/10.1042/bst20250441
Vancouver
Bertran-Mostazo A, Barrio R. Rewriting protein fate: emerging strategies for targeted protein degradation and associated challenges. Biochemical Society Transactions. 2026;54(11):1607-1621. doi:10.1042/bst20250441
BibTeX
@article{BertranMostazo2026,
author = {Bertran-Mostazo, Andrea and Barrio, Rosa},
title = {Rewriting protein fate: emerging strategies for targeted protein degradation and associated challenges},
journal = {Biochemical Society Transactions},
year = {2026},
volume = {54},
number = {11},
pages = {1607--1621},
doi = {10.1042/bst20250441}
}
EUVIMED